Gilead Sciences announced this Friday the launch of ALL4LIVER 2023, a fellowship program whose motto is “Diagnostics.” derived. Prioritize” aims to support innovative projects that advance diagnosis, improve linkages to healthcare, and help prioritize viral hepatitis treatments on the public health agenda.
ALL4LIVER will support initiatives targeting hepatitis C, B or D around the world (except in the US).
Organizations have until September 30, 2023 to submit grant applications online through the Gilead Grant Portal. Applications will be reviewed by an independent international committee of experts in the field of viral hepatitis (excluding the United States). Review board members are recognized for their expertise in viral hepatitis research, public health or patient advocacy.
In 2016, the World Health Organization (WHO) set a goal of eliminating viral hepatitis as a public health threat by 2030. With only seven years left to achieve this goal, a global approach in all areas related to hepatitis is urgently needed.
Gilead said it has been working to improve the lives of people living with viral hepatitis for more than two decades and remains committed to helping eliminate viral hepatitis through community-based organizations.
To this end, it supports innovative programs that address the unmet needs of people living with viral hepatitis around the world, he added.
“The disruption caused by the covid-19 pandemic has been profound,” said Danjuma Kamlen Adda, President of the World Hepatitis Alliance. “Now more than ever, support from initiatives such as Gilead’s ALL4LIVER grant is critical to ensuring the It is critical that it continue to receive the attention it deserves, and that we continue to develop innovative strategies to eliminate viral hepatitis.”
“Gilead’s expansion of the ALL4LIVER 2023 fellowship program reflects our commitment to addressing the pressing global challenge of viral hepatitis and creating a healthier future for all people living with liver disease. Through empowering community-based organizations, we aim to promote liver health and Helping make the elimination of viral hepatitis a reality by 2030,” said Alex Kalomparis, Senior Vice President of Public Affairs, Gilead Sciences.
Initially launched in 2021 for the Asia-Pacific region, the ALL4LIVER grant has provided more than $1 million in funding to support initiatives to improve viral hepatitis education, with a focus on chronic hepatitis B in the region. Gilead expands ALL4LIVER globally, supporting programs in Europe, Africa, South America, Asia, Colombia and North America (excluding the United States).